AI-Based Prediction of Early Relapse after CAR-T Therapy (ICBMT 2026) - Oct 8, 2026 - Abstract #SS06-2; Pres time: Sep 18, 2026; 10:40 AM - 11:10 AM; Location: Room C(2F); "Accumulating real-world (RW) evidence of axicabtagene ciloleucel (axi-cel) has demonstrated comparable performance to that of pivotal trials...We believe that the power of AI and ML approaches, supported by prospective clinical collection of data within electronic medical records systems, have the potential to significantly improve our approach to identify early predictors of critical events after CAR-T therapy, which include the development of severe toxicities and relapse. Our study demonstrates proof of principle that AI-driven analysis of cellular therapy data can be refined and ultimately might guide better clinical practices."
CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • CRP
|